guest ::
| Home > Publications database > Blood metal levels and amyotrophic lateral sclerosis risk: a prospective cohort. > print |
| Home > Publications database > Blood metal levels and amyotrophic lateral sclerosis risk: a prospective cohort. > print |
| 001 | 164045 | ||
| 005 | 20240229133511.0 | ||
| 024 | 7 | _ | |a 10.1002/ana.25932 |2 doi |
| 024 | 7 | _ | |a pmid:33068316 |2 pmid |
| 024 | 7 | _ | |a 0364-5134 |2 ISSN |
| 024 | 7 | _ | |a 1531-8249 |2 ISSN |
| 024 | 7 | _ | |a altmetric:92595510 |2 altmetric |
| 037 | _ | _ | |a DKFZ-2020-02213 |
| 041 | _ | _ | |a eng |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Peters, Susan |0 0000-0001-5662-1971 |b 0 |
| 245 | _ | _ | |a Blood metal levels and amyotrophic lateral sclerosis risk: a prospective cohort. |
| 260 | _ | _ | |a Hoboken, NJ |c 2021 |b Wiley-Blackwell |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1614876402_3140 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 500 | _ | _ | |a 2021 Jan;89(1):125-133 |
| 520 | _ | _ | |a Metals have been suggested as risk factor for amyotrophic lateral sclerosis (ALS), but only retrospective studies are available to date. We compared metal levels in prospectively collected blood samples from ALS patients and controls, to explore whether metals are associated with ALS mortality.A nested ALS case-control study was conducted within the prospective EPIC cohort. Cases were identified through death certificates. We analyzed metal levels in erythrocyte samples obtained at recruitment, as biomarker for metal exposure from any source. Arsenic, cadmium, copper, lead, manganese, mercury, selenium and zinc concentrations were measured by inductively coupled plasma-mass spectrometry. To estimate ALS risk, we applied conditional logistic regression models.The study population comprised 107 cases (65% female) and 319 controls matched for age, sex and study center. Median time between blood collection and ALS death was 8 years (range 1-15). Comparing the highest with the lowest tertile, cadmium (odds ratio (OR) 2.04, 95% confidence interval (CI) 1.08-3.87) and lead (OR 1.89, 95%CI 0.97-3.67) concentrations suggest associations with increased ALS risk. Zinc was associated with a decreased risk (OR 0.50, 95%CI 0.27-0.94). Associations for cadmium and lead remained when limiting analyses to non-current smokers.This is the first study to compare metal levels before disease onset, minimizing reverse causation. The observed associations suggest that cadmium, lead and zinc may play a role in ALS etiology. Cadmium and lead possibly act as intermediates on the pathway from smoking to ALS. This article is protected by copyright. All rights reserved. |
| 536 | _ | _ | |a 313 - Krebsrisikofaktoren und Prävention (POF4-313) |0 G:(DE-HGF)POF4-313 |c POF4-313 |x 0 |f POF IV |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, |
| 700 | 1 | _ | |a Broberg, Karin |b 1 |
| 700 | 1 | _ | |a Gallo, Valentina |0 0000-0002-1268-8629 |b 2 |
| 700 | 1 | _ | |a Levi, Michael |b 3 |
| 700 | 1 | _ | |a Kippler, Maria |b 4 |
| 700 | 1 | _ | |a Vineis, Paolo |b 5 |
| 700 | 1 | _ | |a Veldink, Jan |b 6 |
| 700 | 1 | _ | |a van den Berg, Leonard |b 7 |
| 700 | 1 | _ | |a Middleton, Lefkos |b 8 |
| 700 | 1 | _ | |a Travis, Ruth C |b 9 |
| 700 | 1 | _ | |a Bergmann, Manuela M |b 10 |
| 700 | 1 | _ | |a Palli, Domenico |b 11 |
| 700 | 1 | _ | |a Grioni, Sara |b 12 |
| 700 | 1 | _ | |a Tumino, Rosario |b 13 |
| 700 | 1 | _ | |a Elbaz, Alexis |0 0000-0001-9724-5490 |b 14 |
| 700 | 1 | _ | |a Vlaar, Tim |b 15 |
| 700 | 1 | _ | |a Mancini, Francesca |b 16 |
| 700 | 1 | _ | |a Kühn, Tilman |0 P:(DE-He78)0907a10ba1dc8f53f04907f54f6fdcfe |b 17 |u dkfz |
| 700 | 1 | _ | |a Katzke, Verena |0 P:(DE-He78)fb68a9386399d72d84f7f34cfc6048b4 |b 18 |u dkfz |
| 700 | 1 | _ | |a Agudo, Antonio |b 19 |
| 700 | 1 | _ | |a Goñi, Fernando |b 20 |
| 700 | 1 | _ | |a Gómez, Jesús-Humberto |b 21 |
| 700 | 1 | _ | |a Rodríguez-Barranco, Miguel |b 22 |
| 700 | 1 | _ | |a Merino, Susana |0 0000-0001-8998-4787 |b 23 |
| 700 | 1 | _ | |a Barricarte, Aurelio |b 24 |
| 700 | 1 | _ | |a Trichopoulou, Antonia |b 25 |
| 700 | 1 | _ | |a Jenab, Mazda |b 26 |
| 700 | 1 | _ | |a Weiderpass, Elisabete |0 0000-0003-2237-0128 |b 27 |
| 700 | 1 | _ | |a Vermeulen, Roel |b 28 |
| 773 | _ | _ | |a 10.1002/ana.25932 |g p. ana.25932 |0 PERI:(DE-600)2037912-2 |n 1 |p 125-133 |t Annals of neurology |v 89 |y 2021 |x 1531-8249 |
| 909 | C | O | |o oai:inrepo02.dkfz.de:164045 |p VDB |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 17 |6 P:(DE-He78)0907a10ba1dc8f53f04907f54f6fdcfe |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 18 |6 P:(DE-He78)fb68a9386399d72d84f7f34cfc6048b4 |
| 913 | 0 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF3-310 |0 G:(DE-HGF)POF3-313 |3 G:(DE-HGF)POF3 |2 G:(DE-HGF)POF3-300 |4 G:(DE-HGF)POF |v Cancer risk factors and prevention |x 0 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF4-310 |0 G:(DE-HGF)POF4-313 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Krebsrisikofaktoren und Prävention |x 0 |
| 914 | 1 | _ | |y 2021 |
| 915 | _ | _ | |a Nationallizenz |0 StatID:(DE-HGF)0420 |2 StatID |d 2020-02-26 |w ger |
| 915 | _ | _ | |a DEAL Wiley |0 StatID:(DE-HGF)3001 |2 StatID |d 2020-02-26 |w ger |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b ANN NEUROL : 2018 |d 2020-02-26 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2020-02-26 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2020-02-26 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0310 |2 StatID |b NCBI Molecular Biology Database |d 2020-02-26 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2020-02-26 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |d 2020-02-26 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0110 |2 StatID |b Science Citation Index |d 2020-02-26 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2020-02-26 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0111 |2 StatID |b Science Citation Index Expanded |d 2020-02-26 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2020-02-26 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1190 |2 StatID |b Biological Abstracts |d 2020-02-26 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |d 2020-02-26 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2020-02-26 |
| 915 | _ | _ | |a IF >= 5 |0 StatID:(DE-HGF)9905 |2 StatID |b ANN NEUROL : 2018 |d 2020-02-26 |
| 920 | 1 | _ | |0 I:(DE-He78)C020-20160331 |k C020 |l C020 Epidemiologie von Krebs |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)C020-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|